Ananda Pharma PLC has announced plans to withdraw its shares from the AQSE Growth Market and re-register as a private company, proposing to continue operations under the name Ananda Pharma
Ananda Pharma PLC has announced plans to withdraw its shares from the AQSE Growth Market and re-register as a private company, proposing to continue operations under the name Ananda Pharma
Ananda Pharma PLC has announced plans to withdraw from the AQSE Growth Market and re-register as a private company, citing the high cost of being publicly listed, regulatory complexity and
Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that the post annual report corporate
Ananda Pharma plc (AQSE: ANA), a UK company focused on the development of cannabinoid therapies targeting the treatment of complex, chronic inflammatory pain conditions is pleased to announce the appointment of Andy Rust as
Ondo InsurTech (ONDO), the London-listed leader in claims prevention technology for home insurers, announced its unaudited results for the six-month period ended 30 September 2024. Revenue grew by 42% to £1.7
Finance Director Jeremy Sturgess-Smith introduces Ananda Developments, outlining the company’s mission, strategic focus, and what makes it distinct within the CBD and drug development sectors.
The Growth Government
Overnight the headline waiting as one opened one’s phone was that “Trump Shot.” By the sound of it so far, this headline could have been “Trump Assassinated.” Perhaps the most interesting part of the
The Czech Is Still In The Post There are of course many issues in this country that drive one to despair. Perhaps the worst things is not having a third
The FTSE 100 ended the week up 1.75%, with the Small Caps index up 1.4%.
Ananda Developments Plc (AQSE: ANA), a developer of cannabinoid medicines, has secured the necessary funding to initiate a trial to test the effectiveness of its cannabidiol oil, MRX1, in treating
Ananda’s ambition is to be a leading provider of high-quality cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.